Researchers say lerociclib plus fulvestrant could become a new treatment option for HR+/HER2- advanced breast cancer, but lerociclib is not approved in the US.

The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Incorporating mpMRI into initial staging before TURBT reduces the time to correct treatment for patients with MIBC.

New research suggests that firstborn twins may have a greater risk of developing leukemia than second-born twins.

Baseline geriatric vulnerabilities and QOL scores are associated with survival after chemotherapy in older adults with metastatic pancreatic cancer, researchers found.